コディアック DAYBREAK第3相試験、ZenkudaとKSI-501のトップラインデータは2026年9月公表予定

The 8-K confirms the DAYBREAK Phase 3 study of Zenkuda and KSI-501 in treatment-naïve wet AMD remains on track for one-year primary endpoint topline data in September 2026. Enrollment is complete and the company continues BLA preparation activities for Zenkuda. A second Phase 3 readout for KSI-101 in MESI is also guided for December 2026.

主要事実

提出: 2026年8月13日 20:00
イベント: トップライン結果
方向: 中立
企業: KODコディアック・サイエンス
アセット: Zenkuda
出典: SEC 8-K
信頼度: 出典あり
DRSS 2段階改善: 62.5% vs 3.3% (p<0.0001)
STCリスク低下: 85% (2.4% vs 15.8%, p=0.0001)

出典の抜粋

EX-99.1 2 kod-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2026 Financial Results PALO ALTO, Calif., August 13, 2026 -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the second quarter ended June 30, 2026. "Kodiak continues to execute broadly across our late-stage clinical portfolio as we approach three Phase 3 readouts between now and the end of this year," said Victor Perlroth, M.D., Chief Executive Officer of Kodiak Sciences. "We remain on track for September 2026 DAYBREAK Phase 3 topline results evaluating both Zenkuda and KSI-501 in treatment-naïve wet AMD, followed by December 2026 PEAK Phase 3 Pivotal Analysis 1 topline results evaluating KSI-101 in Macular

SEC 8-K